IP Verse

Method And Compositions For Cellular Immunotherapy - EP2689010

The patent EP2689010 was granted to Fred Hutchinson Cancer Center on Nov 18, 2020. The application was originally filed on Mar 23, 2012 under application number EP12725893A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2689010

FRED HUTCHINSON CANCER CENTER
Application Number
EP12725893A
Filing Date
Mar 23, 2012
Status
Granted And Under Opposition
Oct 16, 2020
Grant Date
Nov 18, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEJul 20, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEJul 20, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO1991US08442-
DESCRIPTIONWO1994US05601-
DESCRIPTIONUS2003170238
DESCRIPTIONUS2008131415
DESCRIPTIONUS4690915
DESCRIPTIONUS6040177
DESCRIPTIONUS6344192
DESCRIPTIONUS6410319
DESCRIPTIONUS7446191
DESCRIPTIONUS7514537
DESCRIPTIONWO02077029
DESCRIPTIONWO2007059298
DESCRIPTIONWO2010025177
DESCRIPTIONWO2010065818
INTERNATIONAL-SEARCH-REPORTWO2010025177
OPPOSITIONUS2003134415
OPPOSITIONWO02077029
OPPOSITIONWO2008066609

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- BERGER et al., "Adoptive transfer of virus-specific and tumor-specific T cell immunity", Current Opinion in Immunology, (20090000), vol. 21, no. 2, doi:10.1016/j.coi.2009.02.010, pages 224 - 232, XP026058400
OPPOSITION- TURTLE et al., "Genetically retargeting CD 8+ lymphocyte subsets for cancer immunotherapy", Current Opinion in Immunology, (20110000), vol. 23, no. 2, doi:10.1016/j.coi.2010.12.012, pages 299 - 305, XP028160383
OPPOSITION- MACLEOD et al., "CD 4 memory T cells: what are they and what can they do?", Seminars in Immunology, (20090000), vol. 21, no. 2, doi:10.1016/j.smim.2009.02.006, pages 53 - 61, XP025982853
OPPOSITION- MacLeod, M.K.L. ; Clambey, E.T. ; Kappler, J.W. ; Marrack, P., "CD4 memory T cells: What are they and what can they do?", Seminars in immunology, W.B. SAUNDERS COMPANY, PA., US, US, (20090401), vol. 21, no. 2, doi:10.1016/j.smim.2009.02.006, ISSN 1044-5323, pages 53 - 61, XP025982853
OPPOSITION- BLEAKLEY et al., "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia", Immunology and Cell Biology, (20110000), vol. 89, no. 3, doi:10.1038/icb.2010.124, pages 396 - 407, XP055663061
OPPOSITION- SOMMERMEYER et al., "Chimeric antigen receptor-modified T cells derived from defined CD 8+ and CD 4+ subsets confer superior antitumor reactivity in vivo", Leukemia, (20160000), vol. 30, no. 2, doi:10.1038/leu.2015.247, pages 492 - 500, XP055569635
OPPOSITION- Michael C. Milone et al, "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.", Molecular Therapy, Elsevier Inc., US, US, (20090801), vol. 17, no. 8, doi:10.1038/MT.2009.83, ISSN 1525-0016, pages 1453 - 1464, XP002732433
OPPOSITION- SADELAIN et al., "Targeting tumours with genetically enhanced T lymphocytes", Nature Reviews Cancer, (20030000), vol. 3, no. 1, doi:10.1038/nrc971, pages 35 - 45, XP009026020
OPPOSITION- SADELAIN M, RIVIERE I, BRENTJENS R, "TARGETING TUMOURS WITH GENETICALLY ENHANCED T LYMPHOCYTES", Nature Reviews Cancer, Nature Pub. Group, London, London, (20030101), vol. 03, no. 01, doi:10.1038/nrc971, ISSN 1474-175X, pages 35 - 45, XP009026020
OPPOSITION- JUNE et al., "Engineering lymphocyte subsets: tools, trials and tribulations", Nature Reviews Immunology, (20090000), vol. 9, no. 10, doi:10.1038/nri2635, pages 704 - 716, XP055145648
OPPOSITION- DOTTI et al., "Fifteen years of gene therapy based on chimeric antigen receptors: ''are we nearly there yet?", Human Gene Therapy, (20090000), vol. 20, no. 11, pages 1229 - 1239, XP055122213
OPPOSITION- BEECHAM et al., "Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembrvonic antigen chimeric immunoglobulin T- cell receptor", Journal of Immunotherapy, (20000000), vol. 23, no. 3, doi:10.1097/00002371-200005000-00006, pages 332 - 343, XP055751785
OPPOSITION- Berry L. J., Moeller M., Darcy P. K., "Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells", TISSUE ANTIGENS., MUNKSGAARD, COPENHAGEN., DK, DK, (20091001), vol. 74, no. 4, doi:10.1111/j.1399-0039.2009.01336.x, ISSN 0001-2815, pages 277 - 289, XP055838046
OPPOSITION- TURTLE et al., "Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD 8+ and CD 4+ CD 19-specific chimeric antigen receptor-modified T cells", Cancer, (20160000), vol. 8, no. 355, doi:10.1126/scitranslmed.aaf8621, page 355ra116, XP055538573
OPPOSITION- ZHU et al., "Differentiation of effector CD 4 T cell populations", Annual Review of Immunology, (20100000), vol. 28, doi:10.1146/annurev-immunol-030409-101212, pages 445 - 489, XP055819422
OPPOSITION- CARTELLIERI et al., "Chimeric antigen receptor-engineered T cells for immunotherapy of cancer", Journal of Biomedicine and Biotechnology, (20100000), vol. 956304, doi:10.1155/2010/956304, pages 1 - 13, XP002673541
OPPOSITION- GYOBU et al., "Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T- cell receptor", Cancer Research, (20040000), vol. 64, no. 4, doi:10.1158/0008-5472.CAN-03-2780, pages 1490 - 1495, XP003020171
OPPOSITION- MOELLER et al., "Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene -Modified CD 4+ T Helper-1 and CD 8+ T Cells", Cancer Res, (20070000), vol. 67, no. 23, doi:10.1158/0008-5472.CAN-07-1141, pages 11428 - 11437, XP055080756
OPPOSITION- JUNE, "Principles of adoptive T cell cancer therapy", The Journal of Clinical Investigation, (20070000), vol. 117, no. 5, doi:10.1172/JCI31446, pages 1204 - 1212, XP055761950
OPPOSITION- BERGER et al., "Adoptive transfer of effector CD 8+ T cells derived from central memory cells establishes persistent T cell memory in primates", J Clin Invest, (20080000), vol. 118, no. 1, doi:10.1172/JCI32103, pages 294 - 305, XP055284133
OPPOSITION- MOELLER et al., "Adoptive transfer of gene -engineered CD 4 helper T cells induces potent primary and secondary tumor rejection", Blood, (20050000), vol. 106, no. 9, doi:10.1182/blood-2004-12-4906, pages 2995 - 3003, XP003022406
OPPOSITION- ZHENG et al., "Effector memory CD 4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease", Blood, (20080000), vol. 111, no. 4, doi:10.1182/blood-2007-08-109678, pages 2476 - 2484, XP086506832
OPPOSITION- HUDECEK et al., "The B- cell tumor-associated antigen R0R1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", Immunobiol, (20100000), vol. 116, no. 22, doi:10.1182/blood-2010-05-283309, pages 4532 - 4541, XP055751962
OPPOSITION- Wang Xiuli et al, "Engraftment of human central memory-derived effector CD8 Ï© T cells in immunodeficient mice", Blood, doi:10.1182/blood-2010-10-, (20110101), pages 1888 - 1898, Blood, URL: https://watermark.silverchair.com/zh800611001888.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA-0wggPpBgkqhkiG9w0BBwagggPaMIID1gIBADCCA88GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMmCclubNIXgnN8n9IAgEQgIIDoPf5YypIMFioLmnErKlNjDNrzA0zikG26dwXQ6PqC6sJIDqP9oG8BK7oVPhSm5egXai6xLULCuinMVPGdF6ImcSlyK721WoUzz-_7yJtOW_EWNoTxoJyjltOD_0XJgfNWg10ok55cyWDn14Bh0foR7RA-N50ZZ5A5P3m2lK3g_4_zj2UFaC31LAwf4KuxOEFj6fGdvHa6rtJ9Q03v6FQD8FDgjqMVZqk28AfhStnzGcq4g1eBONFYxEbj4U_CstBhB-bnfbAoUggNOs_ZzVif-48yanSt1z24J7-hK46mvWVPM537PQcdcuEnKvEMsDwU1rItztCyY3czkx4bhaphaL8R_hL_RQp3kRJlPhErZeYX637bmnYiXZ2OAQqKnCQdJMZMRqxKMZYAjrQoiQsivCVDkNCMYGM7hNoAMKKqtLmusQsYMbf8khUQTGb32Zv1ZJj_rqson7BP2y5sxm3RPIpnngYByckd4Gh4OOwX-mqckiVLz7-y15fbBq6qQLtERFGNKEqbOsi-69wodaqAgAvGOjBegDZVoR4r162pJhEhorNqLrpY_5UeqIuxvMeHL4Z-PX03_uTRQIH5AMz1vX2SHWH2jB_4SYHfr110rmDv1gr0pvXyd8xQ4fGVcIPuCZb0k7ga2GSVxRo1re0i8VS4yvS5X7Zidl-nMMht1ILQhVt8N5eXBdi19G_JupX1S-sPNVHjOY2-CC7RhMddDsCk7euaMQQ5Wvz-2N52C064PasvVWKBpOdkoUO49hKJxGoVlUC_OKFeU1R-, (20210906), XP055838056
OPPOSITION- HUDECEK et al., "Naive CD 4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD 8+ ROR1-CAR T Cells", Blood, (20110000), vol. 118, no. 21, doi:10.1182/blood.V118.21.643.643, page 643, XP086624794
OPPOSITION- HUDECEK et al., "Adoptive T- cell therapy for B- cell malignancies", Expert review of hematology, (20090000), vol. 2, no. 5, doi:10.1586/ehm.09.47, pages 517 - 532, XP055034818
OPPOSITION- Bridgeman John S; Hawkins Robert E; Hombach Andreas A; Abken Hinrich; Gilham David E, "Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL, (20100401), vol. 10, no. 2, doi:10.2174/156652310791111001, ISSN 1566-5232, pages 77 - 90, XP009187229

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents